All lobbying filings

THE MCMANUS GROUP

THE MCMANUS GROUP filed a Q2 termination report for FULCRUM THERAPEUTICS on July 20, 2026, reporting $60,000 in lobbying income.

Lobbying for FULCRUM THERAPEUTICS · Rare disease biopharma company

All filings by THE MCMANUS GROUP · Everything FULCRUM THERAPEUTICS has reported

Filing · LD-2 quarterly report Q2 termination

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Representation ended

Jun 30, 2026

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.

Bills named in this filing 2

H.R. 1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
S. 735
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.